GREENWICH LIFESCIENCES, INC. Earnings Per Share (Basic)
GREENWICH LIFESCIENCES, INC. (GLSI) reported Earnings Per Share (Basic) of -$0.27 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.27.
- GREENWICH LIFESCIENCES, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.39.
- GREENWICH LIFESCIENCES, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.27.
- GREENWICH LIFESCIENCES, INC. earnings per share, basic for the quarter ending 2025-06-30 was -$0.28.
- GREENWICH LIFESCIENCES, INC. earnings per share, basic for fiscal 2025 was -$1.43.
- GREENWICH LIFESCIENCES, INC. earnings per share, basic for fiscal 2024 was -$1.34.
- GREENWICH LIFESCIENCES, INC. earnings per share, basic for fiscal 2023 was -$0.69.
- GREENWICH LIFESCIENCES, INC. earnings per share, basic for fiscal 2022 was -$0.61.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.27 10-Q · filed 2026-08-11 | -$0.65 10-Q · filed 2026-08-11 | ||||||
| 2026-03-31 | -$0.39 10-Q · filed 2026-06-04 | |||||||
| 2025-12-31 | -$1.43 10-K · filed 2026-06-01 | |||||||
| 2025-09-30 | -$0.27 10-K · filed 2026-06-01 | -$0.30 10-Q · filed 2025-11-14 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.76 10-K · filed 2026-06-01 | -$0.85 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$0.28 10-Q · filed 2026-08-11 | -$0.30 10-Q · filed 2025-08-14 | -$0.49 10-Q · filed 2026-08-11 | -$0.55 10-Q · filed 2025-08-14 | ||||
| 2025-03-31 | -$0.21 10-Q · filed 2026-06-04 | -$0.25 10-Q · filed 2025-05-20 | ||||||
| 2024-12-31 | -$1.34 10-K · filed 2026-06-01 | -$1.21 10-K · filed 2025-04-15 | ||||||
| 2024-09-30 | -$0.20 10-Q · filed 2025-11-14 | -$0.41 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$0.60 10-Q · filed 2025-11-14 | |||||
| 2024-06-30 | -$0.20 10-Q · filed 2025-08-14 | -$0.39 10-Q · filed 2025-08-14 | ||||||
| 2024-03-31 | -$0.19 10-Q · filed 2025-05-20 | |||||||
| 2023-12-31 | -$0.69 10-K · filed 2025-04-15 | |||||||
| 2023-09-30 | -$0.19 10-Q · filed 2024-11-14 | -$0.31 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$0.48 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | -$0.13 10-Q · filed 2024-08-14 | -$0.29 10-Q · filed 2024-08-14 | ||||||
| 2023-03-31 | -$0.17 10-Q · filed 2024-05-20 | |||||||
| 2022-12-31 | -$0.61 10-K · filed 2024-04-15 | |||||||
| 2022-09-30 | -$0.18 10-Q · filed 2023-10-19 | -$0.39 10-Q · filed 2023-10-19 | ||||||
| 2022-06-30 | -$0.06 10-Q · filed 2023-08-21 | -$0.21 10-Q · filed 2023-08-21 | ||||||
| 2022-03-31 | -$0.15 10-Q · filed 2023-05-22 | |||||||
| 2021-12-31 | -$0.35 10-K · filed 2023-03-31 | |||||||
| 2021-09-30 | -$0.07 10-Q · filed 2022-11-14 | -$0.17 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$0.06 10-Q · filed 2022-08-15 | -$0.11 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | -$0.05 10-Q · filed 2022-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |